- Themis medicare received approval for its immunomodulatory antiviral drug VIRALEX® (inosine pranobex) for treatment of covid-19 from Drug Controller General of India (DCGI)
- The drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use as add on therapy for treatment of mild and moderate Covid -19.
- As per the results at the Phase 3 Randomised Double Blind Placebo—Controlled Trial in mild to moderate Covid -19, significantly higher percentage of patients treated with VIRALEX® showed clinical improvement and cure than those who did not receive the drug on day 6 at treatment. There was early improvement and cure from symptoms in patients who received VIRALEX®
Themis Medicare receives approval for immunomodulatory antiviral drug from DCGI
Related Posts
Leave a Reply
Recent News
